Institute For Clinical And Economic Review (icer) - Cancer Science

Relevant Publications

Evaluating the cost-effectiveness of voclosporin for the treatment of lupus nephritis in the United States.

Issue Release: 2024

Access in all areas? A round up of developments in market access and health technology assessment: part 3.

Issue Release: 2024

Cost and Cost-Effectiveness of the Management Strategies of Chronic Urticaria: A Systematic Review.

Issue Release: 2024

Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis.

Issue Release: 2024

Inflation-adjusted analysis of ICER\'s Unsupported Price Increase reports: contextualizing drug spending changes.

Issue Release: 2024

Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment.

Issue Release: 2023

Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Issue Release: 2023

Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER\'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.

Issue Release: 2023

Estimating the value of SGLT2 inhibitors within the context of contemporary guidelines and totality of evidence.

Issue Release: 2023

Managed care considerations to improve health care utilization for patients with ALS.

Issue Release: 2023

Evaluation of Diversity of Clinical Trials Informing Health Technology Assessments in the US: A 5-Year Analysis of ICER Reviews.

Issue Release: 2023

White bagging, brown bagging and site of service policies: best practices in addressing provider markup in the commercial insurance market.

Issue Release: 2023

Institute for Clinical and Economic Review - Peterson Health Technology Institute value assessment framework for digital health technologies.

Issue Release: 2023

Drug Cost-Effectiveness Assessments Require Standards for Rigor and Inclusion.

Issue Release: 2023

Exploring the feasibility of using the ICER Evidence Rating Matrix for Comparative Clinical Effectiveness in assessing treatment benefit and certainty in the clinical evidence on orphan therapies for paediatric indications.

Issue Release: 2023

Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States.

Issue Release: 2023

Patient-centered health technology assessment: a perspective on engagement in health technology assessment by three patient organizations and a health technology assessment body.

Issue Release: 2022

Formulary Submissions: Value Claims, Protocols and Outcomes Based Contracting in Rare Disease.

Issue Release: 2022

Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM).

Issue Release: 2022

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Issue Release: 2022

How do Chromosomal Alterations Lead to Cancer?

What is the Mechanism of Cadmium-Induced Carcinogenesis?

How to Use NCBI API for Cancer Research?

What are Safety Records in Cancer Care?

What Role Does Fatigue Play?

What Is the Prognosis for Cancer Patients with Organ Injury?

How Do Brachytherapy Machines Work?

How Can Cancers Maintain Emotional Balance?

What is the Role of Nurses in Cancer Care?

Why are Clinical Outcomes Important?

Institute For Clinical And Economic Review (icer) - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics